See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Baseball
Natural Disasters
Donald Trump
Social Media
Trade War
Stock Markets
Artificial Intelligence
Education
Nintendo
Democratic Party
Republican Party
Published • loading... • Updated

FDA Approves First and Only Therapy for IgG4-RD

Summary by Medscape
The CD19+ B-Cell targeted therapy reduced flare risk by 87% in a phase 3 clinical trial. Medscape Medical News

3 Articles

All
Left
Center
Right
MedscapeMedscape
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News

FDA Approves First and Only Therapy for IgG4-RD

The CD19+ B-Cell targeted therapy reduced flare risk by 87% in a phase 3 clinical trial. Medscape Medical News

·United States
Read Full Article
Pharmacy TimesPharmacy Times

FDA Approves Inebilizumab to Treat Adult Patients With IgG4-RD

This action makes inebilizumab the first and only FDA-approved treatment for adults with immunoglobulin G4-related disease (IgG4-RD).

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmacy Times broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)

Similar News Topics

Amgen

Amgen

Auto

Auto

FDA

FDA

Medical

Medical

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal